Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor with Azacitidine and Venetoclax in AML based on MRD
NCT05736978Phase 2Recruiting
- Sponsor
- Shanghai Tongren Hospital
- Start
- Mar 2023
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of selinexor in acute myeloid leukemia (AML), sponsored by Shanghai Tongren Hospital. Primary endpoint: Composite Complete Remission up to 2 years. Started Mar 2023; status: recruiting.
02
Drugs
selinexor
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05736978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05736978.